INSIDE PHARMA

INSIDE PHARMA

Share this post

INSIDE PHARMA
INSIDE PHARMA
Challenges in manufacturing and distributing products derived from biologics | Hedley Rees

Challenges in manufacturing and distributing products derived from biologics | Hedley Rees

Explaining the dangers in the 'vaccines' supply chain...

Hedley Rees's avatar
Hedley Rees
May 27, 2024
∙ Paid
7

Share this post

INSIDE PHARMA
INSIDE PHARMA
Challenges in manufacturing and distributing products derived from biologics | Hedley Rees
6
1
Share

Share

This is a presentation to the PANDA Group:

Challenges in manufacturing and distributing products derived from biologics | Hedley Rees

6 September 2023 | The pharmaceutical industry was founded on small molecule products, where active ingredients were manufactured by fine chemical companies using long-established industrial processing. That meant the final dosage forms had excellent stability profiles with a typical shelf-life between two to five years. The simple chemical structures meant that different producers’ products could be tested against specifications and proven to be equivalent and therefore interchangeable. Storage conditions, in the main, were controlled room temperature (20°C), which was relatively easy to maintain within the required +/- 5°C in pharmaceutical warehouses of the day.

Fast forward to today’s industry and the emergence of biologics—products made from living things. With the success of biologics such as monoclonal antibodies in treating certain diseases, rapid …

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 Hedley Rees
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share